NovaBay Pharmaceuticals to Present at H.C. Wainwright 20th Annual Global Investment Conference on September 6

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that management is scheduled to present a corporate overview at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6, 2018 at 2:35 p.m. Eastern time (5:35 p.m. Pacific time). The conference is being held at the St. Regis New York in New York City.

A live webcast and replay will be available on the Investors section of the Company's website at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.

Socialize and Stay informed on NovaBay’s progress:Like us on FacebookFollow us on TwitterConnect with NovaBay on LinkedInJoin us on Google+Visit NovaBay’s Website

View source version on businesswire.com: https://www.businesswire.com/news/home/20180830005065/en/

NovaBay Pharmaceuticals, Inc.For NovaBay Avenova+ purchasing information:Please call us toll free: 1-800-890-0329 or email sales@avenova.comwww.Avenova.comorFrom the Company:Jack McGovern, 510-899-8800Chief Financial Officerjmcgovern@novabay.comorInvestors:LHA Investor RelationsJody Cain, 310-691-7100Jcain@lhai.com

NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024